Literature DB >> 14676781

Outcome of transplantation with unrelated donor bone marrow in children with severe thalassaemia.

S Hongeng1, S Pakakasama, W Chaisiripoomkere, A Chuansumrit, N Sirachainan, A Ungkanont, S Jootar.   

Abstract

SUMMARY: We conducted a study of unrelated donor bone marrow transplantation (BMT) in 11 children with severe thalassaemia. The conditioning regimen consisted of busulphan, cyclophosphamide and antilymphocyte globulin. All received T-cell nondepleted bone marrow. The median marrow-nucleated cell dose was 4.9 x 10(8) /kg (range; 3.5-8.0 x 10(8) /kg). Median time of granulocyte recovery was 16 days (range; 13-21 days), and of platelet recovery was 39 days (range; 14-196). Grade 2-4 acute graft-versus-host disease (GVHD) developed in six patients (54%), and grade 3-4 in one patient (9%). Three (27%) of 11 evaluable patients had chronic GVHD (limited stage). All 11 patients are alive without thalassaemia after a median follow-up time of 397 days (range; 171-814 days). This study lends support to consideration of unrelated donor BMT as an acceptable therapy to cure severe thalassaemia especially in patients who are young and do not yet show irreversible severe complications of iron overload.

Entities:  

Mesh:

Year:  2004        PMID: 14676781     DOI: 10.1038/sj.bmt.1704361

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

1.  Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification.

Authors:  Usanarat Anurathapan; Samart Pakakasama; Pimsiri Mekjaruskul; Nongnuch Sirachainan; Duantida Songdej; Ampaiwan Chuansumrit; Pimlak Charoenkwan; Arunee Jetsrisuparb; Kleebsabai Sanpakit; Bunchoo Pongtanakul; Piya Rujkijyanont; Arunotai Meekaewkunchorn; Rosarin Sruamsiri; Artit Ungkanont; Surapol Issaragrisil; Borje S Andersson; Suradej Hongeng
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-23       Impact factor: 5.742

2.  Multiorgan engraftment and differentiation of human cord blood CD34+ Lin- cells in goats assessed by gene expression profiling.

Authors:  Fanyi Zeng; Mei-jue Chen; Don A Baldwin; Zhi-juan Gong; Jing-bin Yan; Hui Qian; Juan Wang; Xiaoyan Jiang; Zhao-rui Ren; Deming Sun; Shu-zhen Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

3.  Unrelated Umbilical Cord Blood Transplant for Children with β-Thalassemia Major.

Authors:  Sandip A Shah; Kamlesh M Shah; Kinnari A Patel; Asha S Anand; Shailesh S Talati; Harsha P Panchal; Apurva A Patel; Sonia K Parikh; Bhavesh B Parekh; Shilin N Shukla; Shreeniwas S Raut
Journal:  Indian J Hematol Blood Transfus       Date:  2014-06-19       Impact factor: 0.900

4.  A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand.

Authors:  Pattara Leelahavarong; Usa Chaikledkaew; Suradej Hongeng; Vijj Kasemsup; Yoel Lubell; Yot Teerawattananon
Journal:  BMC Health Serv Res       Date:  2010-07-16       Impact factor: 2.655

5.  Hematopoietic stem cell transplantation for people with sickle cell disease.

Authors:  Chioma Oringanje; Eneida Nemecek; Oluseyi Oniyangi
Journal:  Cochrane Database Syst Rev       Date:  2020-07-03

6.  Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program.

Authors:  Rosarin Sruamsiri; Nathorn Chaiyakunapruk; Samart Pakakasama; Somtawin Sirireung; Nintita Sripaiboonkij; Udomsak Bunworasate; Suradej Hongeng
Journal:  BMC Health Serv Res       Date:  2013-02-05       Impact factor: 2.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.